BMC Genomics · 2014 · 14 citations · 1 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsAntiepileptic PharmacologyAntiepileptic PharmacotherapyClinical Implementation Of PharmacogeneticsCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug DispositionAntiepileptic Drug PharmacokineticsCarbamazepine PharmacologyCyp3a5 Genotype EffectsCyp3a5 PharmacogeneticsCyp450-mediated InteractionsCytochrome EnzymesCytochrome P450 Genetic PolymorphismPharmacogenetics In Epilepsy
Background The genetically polymorphic cytochrome P450 enzymes are involved in the metabolism and elimination of a number of widely used drugs. CYP3A5 exhibits remarkable inter-individual differences in the pharmacokinetics of Carbamazepine [1]. The present study was undertaken to investigate the effects of CYP3A5 on the pharmacokinetics of antiepileptic drug Carbamazepine in the epileptic patients showing toxicity.
1